Healthcare Companies Report Growth through FDA Approvals, Agreements and Announcements - Research Report on Johnson & Johnson, Stryker, Vertex, Fonar, and Nordion Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 28, 2013 NEW YORK, November 28, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Stryker Corp. (NYSE: SYK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Fonar Corp. (NASDAQ: FONR), and Nordion Inc. (NYSE: NDZ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Johnson & Johnson Research Report On November 22, 2013, Janssen Therapeutics, a division of Janssen Products, LP, which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, reported that the US Food and Drug Administration (FDA) has approved OLYSIO™ (simeprevir). According to the Company, OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells. Douglas Dieterich, M.D., Professor of Medicine in the Division of Liver Diseases, Mount Sinai School of Medicine, and Clinical Trial Investigator for OLYSIO^TM, stated, "Given the complexity of the condition, OLYSIO^TM was studied in a number of different patient populations, including individuals who have relapsed or failed to respond to previous treatments. The FDA approval of OLYSIO^TM is an important milestone for people living with chronic hepatitis C as it means that patients have a new treatment option with the potential to cure this challenging disease." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/07a8_JNJ -- Stryker Corp. Research Report On November 25, 2013, Stryker Corp.'s (Stryker) stock went up by 0.62% at $74.74 per share. Over the past three trading days, the Company's stock increased by 1.29%, compared to the Dow Jones Industrial Average which went up by 1.08% over the same period. The Full Research Report on Stryker Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5b34_SYK -- Vertex Pharmaceuticals Incorporated Research Report On November 20, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that it has sold its royalty rights relating to INCIVO® (telaprevir) to Janssen Pharmaceutica N.V. According to Vertex, pursuant to the agreement Janssen will make a cash payment of $152 million to the Company by Q4 2013 and will cease paying royalties to Vertex on INCIVO sales starting 2014. Commenting on the release, Ian Smith, Executive Vice President and CFO of the Company, stated, "The monetization of INCIVO royalties provides cash to enhance our corporate financial position and continues to position us to support our investment in cystic fibrosis and to advance other key opportunities in our pipeline." Additionally, consequent to the amendment of the companies' 2006 collaboration agreement to develop and commercialize INCIVO in Europe and other regions, Janssen will have sole authority to execute INCIVO marketing and promotion activities in these regions. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e696_VRTX -- Fonar Corp. Research Report On November 25, 2013, Fonar Corp.'s (Fonar) stock went down by 9.35% as it closed the day at $19.01 per share. However, over the previous three trading day period, the Company's stock was up by 8.88%, compared to the Dow Jones Industrial Average which went up by 1.08% during the same trading period. The Full Research Report on Fonar Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/73cc_FONR -- Nordion Inc. Research Report On November 25, 2013, Nordion Inc.'s (Nordion) stock closed at $8.30 per share, reflecting a decrease of 0.24%. Over the past three trading day period, the Company's stock showed an increase of 0.24%, compared to the S&P 500 which went up by 1.19% during the same period. The Full Research Report on Nordion Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/c1d5_NDZ ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Healthcare Companies Report Growth through FDA Approvals, Agreements and Announcements - Research Report on Johnson & Johnson,
Press spacebar to pause and continue. Press esc to stop.